Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIERCE: Neoadjuvant TAS-102 With Concurrent Radiation in Rectal Cancer
NCT04104139Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in rectal adenocarcinoma, sponsored by OHSU Knight Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 8 weeks. Started Dec 2019; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04104139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104139.